RecruitingNot ApplicableNCT06395506

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation

An Open-label Randomized Trial of Exercise ± Creatine Supplementation to Augment the Adaptations of Exercise Training in Cancer Survivors

Sponsor

The University of Texas Medical Branch, Galveston

Enrollment

60 participants

Start Date

Oct 29, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Breast Cancer Female Muscle Weakness

Summary

The study's purpose is to evaluate whether creatine supplementation can help breast cancer survivors respond quicker to exercise by improving strength, endurance, and body composition. We are seeking to compare information collected from healthy woman of the same age who have never had breast cancer to those participants who have had breast cancer and undergone chemotherapy treatment.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether creatine supplements combined with a structured exercise program can help cancer survivors rebuild muscle strength and reduce fatigue during and after treatment. **You may be eligible if...** - You are a cancer survivor (any cancer type) currently receiving treatment or within 1 year of completing treatment - You are able to participate in a supervised exercise program - You are at least 18 years old - You are not currently taking creatine supplements **You may NOT be eligible if...** - You have kidney disease (creatine can affect kidney function) - You have a physical condition that prevents exercise participation - You are pregnant or breastfeeding - You have an allergy to creatine Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTCreatine

Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.